Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Clinical data of cabozantinib to be presented at ASCO meeting

Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.

8 May 2013

Combination therapies may advance treatment for anaplastic thyroid cancer

A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.

19 Apr 2013

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.

15 Apr 2013

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Late stage thyroid cancer patients with aggressive disease may benefit from a genetic test, but experts caution that use of this test in early stage patients is inappropriate because it is unlikely to lead to better outcomes.

11 Apr 2013

BRAF genetic mutation increases mortality among patients with papillary thyroid cancer

Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.

10 Apr 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

ARIAD Pharmaceuticals, Inc. today announced the presentation of preclinical data on ponatinib (Iclusig) , at the American Association for Cancer Research Annual Meeting 2013, in Washington.

9 Apr 2013

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute.

28 Mar 2013

Fukushima report sheds light on future health risks

A detailed report carried out by the World Health Organization estimates that the risk to the general public inside and outside Japan from the Fukushima nuclear accident is minimal with no anticipated increases in cancer rates.

6 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Ill health more likely to be responsible for retirement in regional areas than in cities

Men and women of working age, living in regional areas are more likely to be fully retired because of ill health than their city counterparts, University of Sydney research shows.

26 Feb 2013

U.N. report examines links between man-made chemicals, health issues

"Man-made chemicals in everyday products are likely to be at least the partial cause of a global surge in birth deformities, hormonal cancers and psychiatric diseases, a U.N.-sponsored research team reported on Tuesday," Reuters reports.

21 Feb 2013

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Cook Medical is the world’s largest privately held medical device manufacturer. The ENT division is Cook’s 10th business unit/clinical division and we are excited to meet the needs of ENT patients.

From COOK MEDICAL INC. 18 Feb 2013

Subclinical hypothyroidism not prognostic in thyroid carcinoma

Subclinical hypothyroidism is not an independent predictor for clinical outcomes in patients with papillary thyroid carcinoma, research shows.

5 Feb 2013

Combination of pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer

A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine.

9 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

Study finds increased risk of cancers among rescue/recovery workers after WTC terrorist attack

Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.

21 Dec 2012

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

As many as 50 percent of all human protein-coding genes are regulated by microRNA (miRNA) molecules. While some miRNAs impact onset and progression of cancer, others can actually suppress the development of malignant tumors and are useful in cancer therapy. They can also serve as potential biomarkers for early cancer detection. In a new issue of Cancer Biomarkers, investigators report on non-coding miRNAs as appealing biomarkers for malignancy.

20 Dec 2012

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Clinical data of cabozantinib to be presented at ASCO meeting

Combination therapies may advance treatment for anaplastic thyroid cancer

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

BRAF genetic mutation increases mortality among patients with papillary thyroid cancer

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

Fukushima report sheds light on future health risks

EpiCept fourth quarter revenue decreases to $0.1 million

Ill health more likely to be responsible for retirement in regional areas than in cities

U.N. report examines links between man-made chemicals, health issues

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Subclinical hypothyroidism not prognostic in thyroid carcinoma

Combination of pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Study finds increased risk of cancers among rescue/recovery workers after WTC terrorist attack

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

Radioactive iodine benefits selected papillary thyroid cancer patients

Genzyme receives EC approval for Thyrogen product label expansion

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in